Business Context and Reporting Period
This Form 8-K was filed by Aeglea BioTherapeutics, Inc. (not Spyre Therapeutics, Inc.) on January 13, 2023. The filing addresses a notice received from The Nasdaq Stock Market regarding the company's compliance with listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price deficiency: the closing bid price of the Common Stock remained below the $1.00 per share minimum requirement for 30 consecutive trading days.
Material Changes
The material change reported is the failure to satisfy the Nasdaq Listing Rule 5450(a)(1) Minimum Bid Price Requirement. This deficiency triggered a formal notice of potential delisting from The Nasdaq Global Market.
Outlook, Risks, and Management Commentary
- Compliance Period: The company has been granted an initial 180-day compliance period to regain compliance, ending on July 12, 2023.
- Remediation Requirement: To maintain listing, the closing bid price must be at least $1.00 per share for a minimum of 10 consecutive trading days prior to the deadline.
- Alternative Options: If compliance is not met by July 12, 2023, the company may be eligible for an additional 180-day period if it transfers to The Nasdaq Capital Market, subject to meeting other listing standards.
- Risks: There is no assurance the company will regain compliance or receive further extensions. Failure to comply could result in delisting.
- Management Action: The company intends to monitor the stock price and consider available options to resolve the noncompliance.
Investor Verification Checklist
- Verify the current closing bid price of Aeglea BioTherapeutics (AGLE) to assess progress toward the $1.00 threshold.
- Monitor for any announcements regarding a reverse stock split or other corporate actions intended to increase the share price.
- Check for updates on the company's intention to transfer to The Nasdaq Capital Market if the initial compliance period expires.
- Review the company's cash position in subsequent filings to ensure sufficient liquidity to operate during the compliance period.